W Lu, M Kostic, T Zhang, J Che, MP Patricelli… - RSC chemical …, 2021 - pubs.rsc.org
Targeted covalent inhibitors have regained widespread attention in drug discovery and have emerged as powerful tools for basic biomedical research. Fueled by considerable …
S Mallal, D Nolan, C Witt, G Masel, AM Martin, C Moore… - The Lancet, 2002 - thelancet.com
Background The use of abacavir a potent HIV—1 nucleosideanalogue reverse— transcriptase inhibitor is complicated by a potentially life-threatening hypersensitivity …
DA Ostrov, BJ Grant, YA Pompeu… - Proceedings of the …, 2012 - National Acad Sciences
Idiosyncratic adverse drug reactions are unpredictable, dose-independent and potentially life threatening; this makes them a major factor contributing to the cost and uncertainty of …
A Singh, TK Bhat, OP Sharma - J Clinic Toxicol S, 2011 - academia.edu
Liver plays a central role in the metabolism and excretion of xenobiotics which makes it highly susceptible to their adverse and toxic effects. Liver injury caused by various toxic …
KD White, WH Chung, SI Hung, S Mallal… - Journal of Allergy and …, 2015 - Elsevier
Immune-mediated (IM) adverse drug reactions (ADRs) are an underrecognized source of preventable morbidity, mortality, and cost. Increasingly, genetic variation in the HLA loci is …
AS Kalgutkar, I Gardner, RS Obach… - Current drug …, 2005 - ingentaconnect.com
The occurrence of idiosyncratic adverse drug reactions during late clinical trials or after a drug has been released can lead to a severe restriction in its use and even in its withdrawal …
AM Martin, D Nolan, S Gaudieri… - Proceedings of the …, 2004 - National Acad Sciences
Susceptibility to a clinically significant drug hypersensitivity syndrome associated with abacavir use seems to have a strong genetic component. We have previously shown that …
Microbial pathogens including Enterobacteriaceae family members bear different antibiotic resistance genes comprising Extended-Spectrum-ß-Lactamases (ESBLs) and Metallo-ß …
NR Kitteringham, RE Jenkins, CS Lane… - … of Chromatography B, 2009 - Elsevier
The conventional pipeline for biomarker development involves a discovery phase, typically conducted by mass spectrometry (MS), followed by validation and clinical application …